89bio’s $125M offering; Another FDA hold for Kezar

Plus, news about Nip­pon Shinyaku, At­se­na, Or­na Ther­a­peu­tics, Ovid Ther­a­peu­tics, Gravi­ton Bio­science, Eu­prax­ia, En­tero Ther­a­peu­tics, Jour­ney Ther­a­peu­tics, Ther­a­vance Bio­phar­ma, Al­pha Cog­ni­tion and Tra­vere Ther­a­peu­tics: …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.